Thermoperfusion chemotherapy is a new therapy that combines chemotherapy and thermotherapy to treat tumors. Thermoperfusion chemotherapy is a technique that instills heated chemotherapy drugs into the thoracic and abdominal cavities to improve the efficacy of the drugs through the coordinated effect of heat killing and chemotherapy killing. Its indications are: advanced malignant tumor, combined with refractory thoracoabdominal fluid. The principle is to use physical energy to heat the chemotherapeutic drugs with good thermal effect and infuse them into the tumor site to make the temperature of tumor tissue rise to the effective treatment temperature and maintain it for a certain period of time, using the difference in temperature tolerance ability between normal tissue and tumor cells to achieve the treatment purpose of not only making tumor cells apoptosis but also not damaging normal tissue. Because the operation is relatively simple and low cost, it is not time-consuming or time-consuming and does not increase trauma, and it can be done by placing fixed drainage devices on the basis of thoracic or abdominal penetration. Thermal perfusion chemotherapy is a new recruit in the comprehensive treatment. It allows heat therapy to have an organic and complementary effect with chemotherapy infused drugs, increasing the patient’s sensitivity to chemotherapy. It can kill malignant tumor cells more effectively, improve the patient’s survival quality and prolong the patient’s life, and at the same time reduce the side effects of radiotherapy and chemotherapy, which is called “green therapy” by the international medical community. If thermal infusion chemotherapy and intravenous chemotherapy can be carried out in sequence, it can greatly improve the treatment effect of tumor. I. What is thermal infusion chemotherapy? Heat infusion chemotherapy is a new therapy that combines chemotherapy and heat therapy to treat tumors. The treatment principle of thermal infusion chemotherapy. The principle is to use physical energy to heat the chemotherapeutic drugs with good thermal effect and infuse them into the tumor site to make the temperature of tumor tissue rise to the effective treatment temperature (42.5℃-43.5℃) for 60-120 minutes to achieve a method that not only destroys tumor cells but also does not damage normal tissues (the safe limit of normal tissue cell temperature is 45℃±1℃). Thermal perfusion chemotherapy not only has a direct cytotoxic effect on tumor cells, but also can enhance the efficacy of chemotherapy and radiotherapy, improve the immunity of the body and inhibit the metastasis of tumor. The thermal perfusion chemotherapy in China started in the 1990s. Which tumors are suitable for thermal perfusion chemotherapy? It is suitable for the treatment of lung cancer, stomach cancer, esophageal cancer, liver cancer, colorectal cancer (appendiceal mucinous carcinoma), peritoneal pseudomucinous tumor (carcinoma), ovarian cancer (ovarian mucinous tumor or carcinoma), all kinds of sarcoma, breast cancer, chest and abdominal cavity effusion and patients with symptoms such as persistent pain in the late stage. IV. What is the effect of thermal perfusion chemotherapy? Metastasis of abdominal organs, peritoneum and abdominal lymph nodes often occurs in gastrointestinal tumors. Even for patients who have undergone surgical resection, the incidence of abdominal metastasis is very high, which is one of the main causes of death of patients. The median survival is usually a few weeks or months, with a one-year survival rate of less than 10%. In 1980, spratl first proposed continuous peritoneal thermal perfusion chemotherapy, and later, Japan performed CHPP after surgery for gastric cancer that broke through the whole layer, and conducted a systematic randomized group study, which came to a convincing and positive conclusion: the concentration of drugs in the peritoneal tissue during CHPP is much higher than the plasma concentration, even up to 1000 times, and moreover, due to the absorption in the peritoneal cavity, the concentration of drugs in the portal system is also higher than the surrounding blood up to 10 times higher, which is good for the treatment of liver cancer and pancreatic cancer. A prospective study published by Glehen et al. of the University of Lyon, France, showed that intraperitoneal thermochemotherapy has a better therapeutic effect on patients with metastatic gastric cancer, especially those who do not have preoperative ascites and have undergone effective tumor cytoreductive surgery. Glehen believes that tumor cell reduction combined with peritoneal thermochemotherapy is effective in improving the survival of patients with peritoneal metastases from gastric cancer.